시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 혈전성 혈소판 감소성 자반증(TTP) 시장 보고서(2025년)
Thrombotic Thrombocytopenic Purpura (TTP) Global Market Report 2025
상품코드 : 1720906
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,301,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,108,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,914,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

혈전성 혈소판 감소성 자반증(TTP) 시장 규모는 향후 수년간 안정된 성장이 예상될 예정입니다. 은 희소질환 연구에 대한 투자 증가, 희소질환 치료에 대한 정부 보조금 증가, 희소질환의 진단에 있어서의 AI와 머신러닝의 이용 확대, 고령자 인구의 확대, 심혈관 질환의 유병률의 상승 등에 기인한다고 생각됩니다. 기간의 주요 동향은 질병 관리 개선을위한 재조합 ADAMTS13 효소 요법의 개발, 치료 비용 절감을위한 바이오 시밀러 의약품 채택 확대, 정확한 진단을위한 차세대 시퀀싱 및 고급 연구 기술의 사용, TTP의 조기 발견과 다른 혈전 질환과의 감별을 위한 AI 도구의 도입, 환자별 프로파일에 기초한 개인화 치료 접근법의 구축, 희귀질환 연구 이니셔티브에 대한 정부 및 민간 부문의 투자가 포함됩니다.

심혈관 질환의 유병률 증가는 혈전성 혈소판 감소성 자반증(TTP) 시장의 성장을 가속할 것으로 예측됩니다. 질병 증가는 고령화, 식생활 교란, 운동 부족, 비만, 흡연, 과도한 알코올 섭취, 스트레스 수준 상승 등의 요인과 관련되어 있습니다. 전신 염증을 일으켜 심혈관 문제를 일으키고, 이들 모두가 고혈압, 심근 경색 및 기타 심혈관 합병증의 위험을 높입니다. 맥성 심장 질환(CHD)에 의한 사망자 수가 2021년 1만 4,100명에서 2022년에는 1만 4,900명으로 증가했다고 보고했습니다.

헬스케어 지출 증가도 혈전성 혈소판 감소성 자반증(TTP) 시장을 밀어 올릴 것으로 예측됩니다. 외출을 가리킵니다.고령화, 의료기술의 진보, 만성질환의 만연, 헬스케어 서비스에 대한 수요 증가 등의 요인이, 헬스케어 지출 증가에 기여하고 있습니다.의 모니터링, 새로운 치료법의 연구 등에 대한 액세스를 향상시키고, 궁극적으로 환자의 결과를 개선하고 합병증을 감소시킴으로써, TTP 시장을 지원하고 있습니다. 올해부터 2023년에 걸쳐 5.6% 증가했다고 보고했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening blood disorder that involves the formation of small blood clots (thrombi) within blood vessels throughout the body. These clots can obstruct blood flow to different organs, potentially causing organ damage. The primary treatment for TTP is plasmapheresis, which removes harmful antibodies and replaces the deficient ADAMTS13 enzyme.

The primary types of thrombotic thrombocytopenic purpura (TTP) are inherited and acquired TTP. Inherited TTP is a rare genetic condition caused by mutations in the ADAMTS13 gene, resulting in impaired breakdown of von Willebrand factor and recurrent clotting episodes. Treatment options for TTP include plasma exchange, corticosteroids, rituximab, caplacizumab, and other therapies. These treatments are used by a variety of end-users, such as hospitals, specialty centers, and other healthcare facilities.

The thrombotic thrombocytopenic purpura (TTP) market research report is one of a series of new reports from The Business Research Company that provides thrombotic thrombocytopenic purpura (TTP) market statistics, including the thrombotic thrombocytopenic purpura (TTP) industry global market size, regional shares, competitors with the thrombotic thrombocytopenic purpura (TTP) market share, detailed thrombotic thrombocytopenic purpura (TTP) market segments, market trends, and opportunities, and any further data you may need to thrive in the thrombotic thrombocytopenic purpura (TTP) industry. This thrombotic thrombocytopenic purpura (TTP) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The thrombotic thrombocytopenic purpura (TTP) market size has grown strongly in recent years. It will grow from $1.00 billion in 2024 to $1.05 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth during the historic period can be attributed to increased awareness of rare blood disorders, a rising prevalence of autoimmune diseases associated with secondary TTP, advancements in immunosuppressive drug formulations, global growth in healthcare infrastructure, a stronger emphasis on patient education programs for chronic diseases, and the introduction of care guidelines for TTP by health organizations.

The thrombotic thrombocytopenic purpura (TTP) market size is expected to see steady growth in the next few years. It will grow to $1.27 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The projected growth in the forecast period can be attributed to increased investment in rare disease research, higher government funding for rare disease treatments, growing use of AI and machine learning in diagnosing rare conditions, an expanding geriatric population, and a rising prevalence of cardiovascular diseases. Key trends during this period include the development of recombinant ADAMTS13 enzyme therapies for improved disease management, the growing adoption of biosimilar drugs to lower treatment costs, the use of next-generation sequencing and advanced lab techniques for accurate diagnosis, the implementation of AI tools for early detection of TTP and differentiation from other thrombotic disorders, the creation of individualized treatment approaches based on patient-specific profiles, and both government and private sector investments in rare disease research initiatives.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the thrombotic thrombocytopenic purpura (TTP) market. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. The rise in these diseases is linked to factors such as an aging population, poor diets, lack of physical activity, obesity, smoking, excessive alcohol consumption, and higher stress levels. Thrombotic thrombocytopenic purpura (TTP) contributes to cardiovascular issues by causing widespread microvascular thrombosis, endothelial dysfunction, and systemic inflammation, all of which increase the risk of hypertension, myocardial infarction, and other cardiovascular complications. For example, in December 2023, the Australian Institute of Health and Welfare, a government agency, reported that deaths from coronary heart disease (CHD) rose to 14,900 in 2022, up from 14,100 in 2021. This increase highlights the impact of cardiovascular diseases, which is driving the growth of the TTP market.

The rise in healthcare spending is also expected to boost the thrombotic thrombocytopenic purpura (TTP) market. Healthcare spending refers to the total expenditure on health services and products, including medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, all aimed at improving or maintaining health. Factors such as an aging population, advances in medical technology, the rising prevalence of chronic diseases, and greater demand for healthcare services contribute to higher healthcare spending. This spending supports the TTP market by enabling better access to advanced diagnostics, life-saving treatments such as plasma exchange and immunosuppressive therapy, ongoing patient monitoring, and research into new therapies, which ultimately improve patient outcomes and reduce complications. For instance, in May 2024, the Office for National Statistics, a UK government department, reported that healthcare spending in the UK increased by 5.6% between 2022 and 2023, compared to a 0.9% growth in 2022. The total healthcare expenditure in the UK was approximately $317.63 billion (£292 billion) in 2023. This rise in healthcare spending is contributing to the growth of the TTP market.

Companies in the TTP market are focusing on developing innovative therapies, such as recombinant enzyme replacement therapy, to improve treatment outcomes and efficacy. Recombinant enzyme replacement therapy involves administering synthetic or bioengineered enzymes to patients with enzyme deficiencies, restoring normal metabolic function. For example, in November 2023, Takeda Pharmaceutical Company Limited, a Japan-based company, introduced ADZYNMA, a recombinant ADAMTS13 enzyme replacement therapy that was approved by the U.S. Food and Drug Administration (FDA). This is the first and only treatment for congenital thrombotic thrombocytopenic purpura (cTTP) in both adult and pediatric patients. cTTP is a rare blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme. Clinical trials supporting ADZYNMA's approval showed that the therapy effectively reduced the risk of acute TTP events, and it is now available in the U.S. for both prophylactic and on-demand treatment.

Major players in the thrombotic thrombocytopenic purpura (ttp) market are Pfizer Inc., Merck & Co. Inc., Carelon Research, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Astellas Pharma, Novartis AG, Eisai Co. Ltd., Octapharma AG, Kite Pharma, Medscape, Omeros Corporation, Rigel Pharmaceuticals Inc.

North America was the largest region in the thrombotic thrombocytopenic purpura (TTP) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in thrombotic thrombocytopenic purpura (TTP) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the thrombotic thrombocytopenic purpura (TTP) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The thrombotic thrombocytopenic purpura (TTP) market consists of revenues earned by entities by providing services such as diagnostic services, immunosuppressive therapy, hospitalization & intensive care services, patient support programs, long-term management and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombotic thrombocytopenic purpura (TTP) market also includes sales of immunosuppressants, plasma-based therapies, monoclonal antibodies, and supportive care treatments. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Thrombotic Thrombocytopenic Purpura (TTP) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on thrombotic thrombocytopenic purpura (ttp) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for thrombotic thrombocytopenic purpura (ttp) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The thrombotic thrombocytopenic purpura (ttp) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Thrombotic Thrombocytopenic Purpura (TTP) Market Characteristics

3. Thrombotic Thrombocytopenic Purpura (TTP) Market Trends And Strategies

4. Thrombotic Thrombocytopenic Purpura (TTP) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Thrombotic Thrombocytopenic Purpura (TTP) Growth Analysis And Strategic Analysis Framework

6. Thrombotic Thrombocytopenic Purpura (TTP) Market Segmentation

7. Thrombotic Thrombocytopenic Purpura (TTP) Market Regional And Country Analysis

8. Asia-Pacific Thrombotic Thrombocytopenic Purpura (TTP) Market

9. China Thrombotic Thrombocytopenic Purpura (TTP) Market

10. India Thrombotic Thrombocytopenic Purpura (TTP) Market

11. Japan Thrombotic Thrombocytopenic Purpura (TTP) Market

12. Australia Thrombotic Thrombocytopenic Purpura (TTP) Market

13. Indonesia Thrombotic Thrombocytopenic Purpura (TTP) Market

14. South Korea Thrombotic Thrombocytopenic Purpura (TTP) Market

15. Western Europe Thrombotic Thrombocytopenic Purpura (TTP) Market

16. UK Thrombotic Thrombocytopenic Purpura (TTP) Market

17. Germany Thrombotic Thrombocytopenic Purpura (TTP) Market

18. France Thrombotic Thrombocytopenic Purpura (TTP) Market

19. Italy Thrombotic Thrombocytopenic Purpura (TTP) Market

20. Spain Thrombotic Thrombocytopenic Purpura (TTP) Market

21. Eastern Europe Thrombotic Thrombocytopenic Purpura (TTP) Market

22. Russia Thrombotic Thrombocytopenic Purpura (TTP) Market

23. North America Thrombotic Thrombocytopenic Purpura (TTP) Market

24. USA Thrombotic Thrombocytopenic Purpura (TTP) Market

25. Canada Thrombotic Thrombocytopenic Purpura (TTP) Market

26. South America Thrombotic Thrombocytopenic Purpura (TTP) Market

27. Brazil Thrombotic Thrombocytopenic Purpura (TTP) Market

28. Middle East Thrombotic Thrombocytopenic Purpura (TTP) Market

29. Africa Thrombotic Thrombocytopenic Purpura (TTP) Market

30. Thrombotic Thrombocytopenic Purpura (TTP) Market Competitive Landscape And Company Profiles

31. Thrombotic Thrombocytopenic Purpura (TTP) Market Other Major And Innovative Companies

32. Global Thrombotic Thrombocytopenic Purpura (TTP) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Thrombotic Thrombocytopenic Purpura (TTP) Market

34. Recent Developments In The Thrombotic Thrombocytopenic Purpura (TTP) Market

35. Thrombotic Thrombocytopenic Purpura (TTP) Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기